Computer Vision Systems Laboratories has executed an agreement with Infrared Sciences to license the rights, title and interest in the intellectual property surrounding the Sentinel BreastScan.

There is no way to fully anticipate the potential organizational and financial burdens on providers as a result of the proposed rule on HIPAA from the Department of Health and Human Services (HHS), according to the American Medical Informatics Association (AIMA).

The National Center for Image-Guided Therapy (NCIGT) at Brigham and Womens Hospital in Boston plans to leverage Siemens Healthcare syngo.via for multimodality visualization.

One hundred cardiologists surveyed about companies that have had the greatest impact in the field of cardiology placed Pfizer, AstraZeneca, Johnson & Johnson, Merck and Sanofi-Aventis at the top. Additionally, cardiologists said that atorvastatin (Lipitor), clopidogrel (Plavix) and carvedilol (Coreg) yielded the best patient outcomes, reported Sermo Client Solutions, which released the results of its survey Aug. 3.

The Centers for Medicare & Medicaid Services (CMS) has issued a final Inpatient Prospective Payment System (IPPS) rule to slightly increase the current Medicare payments to acute care hospitals and long-term inpatient hospitals.

AstraZeneca has received a positive agreement for approval by the European Union (EU) for axanum, an aspirin and esomeprazole combination drug, indicated to prevent cardiovascular (CV) events in high-risk CV patients who need a daily low-dose acetylsalicylic acid (ASA) and who are at risk for gastric ulcers.

Microscopic gold particles could multiply the effectiveness of standard cancer radiation therapy by acting as tiny missiles that destroy blood vessels feeding cancerous tumors. Early research about this method, which could shorten cancer treatment and make it more effective, is being presented at the 2011 Joint Meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists (COMP).

In a response to the FDAs resubmittal of a complete response letter regarding Bydureon, a weekly exenatide injection indicated to treat type 2 diabetes, the drug's makers Amylin Pharmaceuticals, Eli Lilly and Alkermes said that they have submitted a reply letter and expect to receive an updated Prescription Drug User Free Act (PDUFA) action date from the agency within the next two weeks.